Abstract: FR-PO0255
Cost-Effectiveness Analysis of Tenapanor in Japanese Patients with Hyperphosphatemia on Hemodialysis
Session Information
- Bone and Mineral Metabolism: Clinical Epidemiology and Outcomes
November 07, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Bone and Mineral Metabolism
- 502 Bone and Mineral Metabolism: Clinical
Authors
- Tokunaga, Shin, Kyowa Kirin Co., Ltd., Tokyo, Japan
- Goto, Shunsuke, Kobe University Graduate School of Medicine, Kobe, Japan
- Shimoda, Hiroo, Kyowa Kirin Co., Ltd., Tokyo, Japan
- Igarashi, Ataru, The University of Tokyo, Tokyo, Japan
- Hanada, Keigo, CRECON Medical Assessment Inc., Tokyo, Japan
- Tashiro, Naoki, CRECON Medical Assessment Inc., Tokyo, Japan
- Murata, Tatsunori, CRECON Medical Assessment Inc., Tokyo, Japan
- Asada, Shinji, Kyowa Kirin Co., Ltd., Tokyo, Japan
Background
Tenapanor is a novel treatment for hyperphosphatemia that inhibits sodium/proton exchanger 3. In this study in Japanese hemodialysis patients with hyperphosphatemia, we conducted a cost-effectiveness analysis of Tenapanor from the public healthcare payer’s perspective.
Methods
We divided the subjects into two groups. Group A included patients who were controlled with phosphate binders (PBs) and in whom Tenapanor was compared with ferric citrate. Group B included patients who were uncontrolled with PBs and in whom Tenapanor plus PBs was compared with PBs. The incremental cost effectiveness ratio (ICER) for each group was calculated using a decision tree and Markov model based on the cost per quality adjusted life year (QALY) gained over a lifetime horizon.
Results
In Group A, Tenapanor was estimated to have an incremental effectiveness of +0.355 QALYs compared to ferric citrate, with an ICER of 3,769,893 JPY per QALY. In Group B, Tenapanor plus PBs was estimated to have an incremental effectiveness of +0.753 QALYs compared to PBs, with an ICER of 3,414,644 JPY per QALY (Table 1).
Conclusion
From a Japanese public healthcare payer’s perspective, Tenapanor was cost-effective in both groups, satisfying the threshold of 5 million JPY (approximately 33,500 USD) for the Japanese willingness to pay 1).
Reference. 1) Masataka Hasegawa, et al. Value in Health. 2020; 23(1): 43-51.
Table 1. Base-case analysis
| Effectiveness (QALY) | Incremental effectiveness (QALY) | Cost (JPY) | Incremental cost (JPY) | ICER (JPY/QALY) | |
| Group A | |||||
| Tenapanor | 7.579 | 0.355 | 11,659,936 | 1,339,414 | 3,769,893 |
| Ferric citrate | 7.224 | - | 10,320,522 | - | - |
| Group B | |||||
| Tenapanor plus PBs | 7.706 | 0.753 | 11,117,986 | 2,570,429 | 3,414,644 |
| PBs | 6.953 | - | 8,547,558 | - | - |
ICER: Incremental cost-effectiveness ratio, JPY: Japanese yen, PBs: Phosphate binders, QALY: Quality-adjusted life year.
Funding
- Commercial Support – Kyowa Kirin Co., Ltd.